NCT06311474 2026-03-18
RAINBOW
University of California, Los Angeles
Phase NA Completed
Clinical Trials
10 trialsNCT05044819 2026-03-17
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jazz Pharmaceuticals
Phase 4 Active not recruiting
NCT05864846 2026-03-12
EpiCom
Jazz Pharmaceuticals
Phase 4 Active not recruiting
NCT07403266 2026-02-11
Spectrum
Oils4Cure
Phase 3 Recruiting
NCT02962414 2026-02-03
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Novartis
Phase 3 Active not recruiting
NCT05252585 2026-02-03
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
Novartis
Phase 4 Active not recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT05104983 2026-01-22
TSC-STEPS
Children's Hospital Medical Center, Cincinnati
Phase 2 Recruiting
NCT05467397 2026-01-21
Feasibility of [11C]Acetate-PET in LAM and TSC
Brigham and Women's Hospital
Phase 1/2 Active not recruiting
NCT07287202 2025-12-23
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
Sovargen
Phase 1/2 Not yet recruiting